Περίληψη:
Viral drug susceptibility is associated with virologic response to new
treatments. Standardized drug resistance tests are now available, and
data from some clinical trials suggest that the use of drug resistance
testing may be associated with improved virologic outcome. However, drug
resistance testing is complex in terms of performance, interpretation
and clinical application.
HIV-1 drug resistance testing is used across Europe in patient
management, but not in a consistent manner. This is due to differences
in the national approaches to treatment, treatment management and
reimbursement, as well as availability of tests. National guidelines
only exist in some countries. In addition, the laboratory quality
assurance and quality control standards are not applied uniformly. The
EuroGuidelines Group was established to formulate clinical as well as
laboratory guidelines for the use of HIV-1 drug resistance testing that
are specific for the European setting. The group is comprised of
academic clinicians and virologists, scientist from the industry and
representatives of the patient community.
The panel of experts will review these guidelines and update them on a
yearly basis as new scientific evidence becomes available. (C) 2001
Lippincott Williams & Wilkins.
Συγγραφείς:
Miller, V
Vandamme, AM
Loveday, C
Staszewski, S and
Lundgren, J
Youle, M
Ait-Khaled, M
Boucher, C and
Brun-Vezinet, F
Dedes, N
Giaquinto, C
Hertogs, K
Houyez,
F
Perrin, L
Pillay, D
Schmit, JC
Schuurman, R
Lange,
J
Banhegyi, D
Biondi, G
Broekhuizen, A
Bush-Donovan, C
and Camacho, R
Carlier, H
Clavel, F
Clotet, B
Clumeck, N
and Colebunders, R
De Clerq, K
De Jaegher, JJ
De Schrijver,
G
De Smet, K
Hall, W
Harrigan, R
Hatzakis, A and
Hellmann, N
Hoetelmans, R
Holtzer, C
Katlama, C
Larder,
D
Loriaux, E
McCreedy, B
Mulcahy, F
Opravil, M and
Phillips, A
Ruiz, N
Shulse, E
Sonnerborg, A
Soriano, V
and Steel, H
Vella, S
Williams, A
EuroGuidelines Grp HIV
Resistance
